Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
BACKGROUND
As a result of their polypeptidic nature, hirudins could theoretically elicit an immunologic response in humans.


METHODS
The present open survey evaluates the allergenic potential of recombinant hirudin CGP 39393 (REVASC) after repeated intravenous or subcutaneous exposures in immunocompetent volunteers with no known previous exposure to hirudins. Clinical signs and symptoms of allergic manifestations and surrogate markers of allergy (i.e. response to skin tests) were collected before and after each administration of CGP 39393. Hirudin-specific immunoglobulin (Ig)G or IgE antibodies were measured.


RESULTS
Two hundred and sixty-three healthy volunteers were eligible, of whom 12.2% had a history of allergy and 18.3% had a high level of total IgE. No signs or symptoms of allergy directly attributable to CGP 39393 were reported, either during or immediately after a first challenge. Irritative skin reactions, to either the prick or the intradermal skin test, were observed in eight volunteers 28-56 days after the challenge. Three out of 200 volunteers exposed to a second course of CGP 39393 showed signs and symptoms of an allergic reaction. In all but one subject with a pruritic erythema it was possible to rule out a causative role for CGP 39393 (0.50%, 95% confidence limits [CL] 0.01-2.75). Three other volunteers displayed a suspect or a positive immediate-type skin reaction to the follow-up intradermal skin test without any signs or symptoms of allergy. Another asymptomatic volunteer (0.80%, 95% CL: 0.02-4.41) developed a low [i.e. 1+ on the radio-allergosorbent test (RAST) scale] but measurable titre of hirudin-specific IgE antibodies after the second exposure to CGP 39393. A third exposure in five volunteers was clinically uneventful. A positive reaction to the prick test and to the intradermal skin test was observed in one individual.


CONCLUSIONS
Recombinant hirudin CGP 39393 appears to be a weak allergen. Repeated exposures are safe in fully immunocompetent subjects, including those with a history of previous allergies and high levels of total IgE. Type I allergic reactions are rare (i.e. less than 1%) after a second exposure and are limited to the skin. Routine skin tests are not needed to identify patients at risk of developing type I allergic reactions. Hirudin-specific IgE antibodies are rarely seen and then at very low titres.
Close
P
P
Medical and Clinical Department, Ciba-Geigy Ltd, Basle, Switzerland.
Bichler
J
J
Kerry
R
R
Ekman
S
S
Bueller
H R
HR
Kienast
J
J
Marbet
G A
GA
Schramm
W
W
Verstraete
M
M
D000328:Adult; D004306:Dose-Response Relationship, Immunologic; D003875:Drug Eruptions / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D005060:Europe; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006629:Hirudins / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D007121:Immunocompetence; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000187:drug effects / Q000276:immunology; D007262:Infusions, Intravenous; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D012720:Severity of Illness Index; D012882:Skin Tests
D005343:Fibrinolytic Agents; D006629:Hirudins; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D007073:Immunoglobulin E; C060225:desirudin